Palbociclib in Treating Patients W/Relapsed or Refractory Rb Positive Advanced Solid Tumors, NHL, or Histiocytic Disorders W/Activating Alterations in Cell Cycle Genes (Pediatric MATCH)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
-
Clinical Trial Information
Trial Contact: Spinelli, Jennifer; Leffin, Melissa; El-Shami, Jessica
Trial Phone: 321.841.5357 ; 321.841.2008 ; 321.841.3837
-
IRB No: APEC1621I
Protocol Abbrev: APEC1621I
Principal Investigator: Amy A Smith, MD
Phase: Drug: Phase II
Age Group: Adult;Pediatric
Secondary Protocol No: APEC1621I
Treatment: Other: Laboratory Biomarker Analysis; Drug: Palbociclib; Other: Pharmacological Study
Therapies Involved: Chemotherapy
ClinicalTrials.gov ID: NCT03526250
-
Objective
To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with palbociclib with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor activating genetic alterations in cell cycle genes.
-
Key Eligibility
Ages Eligible for Study: 12 Months to 21 Years (Child, Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
